Zhongguo Wang, Ph.D.

(U.S. citizen)

Lexington, MA 02421 781-***-**** (C) ac80qa@r.postjobfree.com

Summary

Highly motivated and productive Medicinal/Synthetic Organic/Process Chemist with strong synthetic skills and industrial experience in Drug Discovery and Development. Specialized skills include:

Multistep Organic Synthesis

Multi-Parallel Library Synthesis (solid and solution)

Purification/Characterization of Highly Unstable Chemical Compounds

RasMol, Mastro and CAChe Modeling,

Live Design

FT-IR and FT-NMR (13C and 1H), qNMR.

Process Chemistry

Microwave Reaction

HPLC (analytical and preparative)

Biotage and Ion Exchange Chromatography

TLC, UV, GC/MS, GC

EPR Operation Interpretation

Software: Votex/dotmatics, ISIS, Chem Draw, SciFinder, and CambridgeSoft E-Notebook.

Experience

FORMA THERAPEUTICS, INC., Watertown, MA 2008 – Present

Scientist

Made significant contributions to three out of the four Forma’s clinical development candidates; actively worked with internal medicinal chemists and guided the external CRO partners (in China and Europe) with expert synthetic chemistry troubleshooting advice during lead optimization; proposed new targets, new synthetic routes, developed enabling chemistry, provided support and technology transfer to CROs and CMO; ensured effective and timely communication between all parties.

Coordinated external FTEs at CROs, clearly articulated goals, objectives, and timelines to ensure on-time delivery of high-quality final target molecules and intermediates.

Stayed abreast of Forma’s internal project synthetic chemistry needs and articulated a strategic view of how internal and external resources can contribute to meet those needs.

Developed and optimized scalable processes for CBP/P300 and NAMPT, lipid metabolism inhibitor (liver-targeted) back up, and protein homeostasis inhibitor programs.

Developed enabling chemistry to access new scaffolds toward efficient syntheses of analogues for SAR development (lipid metabolism inhibitor (liver-targeted) back up and USP28 programs).

Designed, planned and executed multi-step organic syntheses of high-quality small molecules based on SAR analyses as a member of cross-functional development teams.

Transferred optimized synthetic procedures to the CRO partners and supported patent filings and publications.

Designed and optimized IDH1 inhibitors and Glutaminase inhibitors in order to improve drug-like properties. Made significant contributions toward discovering the clinical candidate (both discovery and development). The clinical candidate (Olutasidenib) is in Phase I/II clinical l trial.

Designed and synthesized lipid metabolism inhibitors. The clinical candidate is in Phase I clinical trial. Made synthetic chemistry contributions toward enantioselective syntheses of key intermediates for lipid metabolism inhibitor (liver-targeted) -Back up program.

Designed and optimized PKR inhibitors in order to improve drug-like properties. Developed an efficient, scalable, core synthesis that was transferred to an external CRO and successfully demonstrated on large scale. The clinical candidate is in phase 1 clinical trial.

Worked on several ubiquitin specific proteases (USP) medicinal chemistry projects. Designed and synthesized many novel protein homeostasis inhibitors. Scaled-up key intermediates for these programs.

Designed and synthesized novel allosteric Bcr-Abl kinase inhibitors.

Optimized MCL1 inhibitors, significantly improved the potency of the lead compound.

Optimized lead CDK inhibitors. Found very selective and potent CDK analogs.

Proposed new ideas; designed and synthesized many NAMPT inhibitors to disrupt cancer cell metabolism. Designed novel synthetic route to the key chiral spirocyclopropane core.

Worked on DOS (diversity-oriented synthesis) libraries. Proposed and executed new DEL and DOS libraries.

ANTHILL TECHNOLOGIES INC., Woburn, MA 2007 – 2008

Senior Scientist, Custom Synthesis

Developed an efficient route to synthesize 5 grams of tetraphosphate nucleotide analogs for a partner client.

Synthesized analogs of nature product Fumagillin (core ring structure).

Synthesized diamide analogs and developed a novel method to convert HCl salt.

Synthesized key intermediates for our clients

GPC BIOTECH, INC., (former Mitotix Inc) Waltham, MA 1999 – 2007

Senior Scientist (2006 – 2007)

Scientist II (2002 – 2006)

Scientist I (1999 – 2002)

Designed and synthesized potent novel indenopyrazole analogs as cycle dependent kinase inhibitors. The indenopyrazole analog, RGB-286638 showed good in vivo activities and is in Phase I clinical trial. Developed an efficient scale-up synthetic procedure for RGB-286638

Optimized anti-cancer pyrazolopyrimidone lead compounds. Discovered preclinical candidate RGB-344064 with good oral bioavailability. RGB-344064 showed potent in vivo activity and was nominated for clinical development. Developed an efficient scale-up procedure to access RGB-344064.

Developed a novel efficient synthetic method for the preparation of a pyrido [2, 3-d] pyrimidin-7-one core structure. In support of the lead optimization novel B-raf inhibitors. Identified orally active lead analogs and, Scaled up key intermediates.

Designed and synthesized macrocyclic and acyclic pyrido [2,3, -d] pyrimidone analogs as Bcr-Abl TK inhibitors.

Designed and synthesized prodrugs of cdk inhibitors to improve oral bioavailability and reduce side effect.

Designed and synthesized methotrexate-linked indenopyrazoles for chemical genomic and pulldown study of cdk inhibitors and other kinase inhibitors.

Performed SAR study of E7070/7010 arylindosulfamide analogs as anti-cancer agents.

Designed and synthesized proline-rich member anchor 1(PRiMal) 3-quinuclidinone) analogs for restoration of normal activity of mutant p53 proteins.

Synthesized halofuginone, staurosporine and indolocarbazole analogs for chemical genomic study of kinase inhibitors.

Designed and synthesized key core nitrogen heterocyclic intermediates for SAR development of novel antifungal GGtase inhibitors. Prepared four, five, or six- membered heterocyclic compounds of prenyl transferases inhibitors to improve potency.

Optimized anti-cancer CDC25 lead compounds. Synthesized pentapeptides through solid phase chemistry.

CUBIST PHARMACEUTICALS INC., Cambridge, MA 1997 – 1999

Research Scientist

Designed and synthesized oxadiazole and benzothiazole antibacterial analogs.

Optimized antifungal lead compounds (thiazolidines and biphenyl sulfonamides) through solution and solid phase synthesis (parallel arrays).

Designed and synthesized novel spirocycles and heterocycles as antibacterial agents. Developed a general combinatorial approach to synthesize spirocyclic heterocycles.

Evaluated and set-up combinatorial instrumentation.

FLORIDA STATE UNIVERSITY, Tallahassee, FL 1995 – 1997

Postdoctoral Research Associate, Department of Chemistry

Research Advisor: Professor Robert A. Holton

Achieved the first synthesis of Taxol analogs with thietane (22 steps), azetidine (14 steps), isoazole (13 steps), and pyrazole (11 steps) as the D-ring respectively from 10-deacetylbaccatin III. The key steps of synthesis of the thietane analog synthesis involved the stereo selective opening of the oxetane ring with TiCl4, [3,3]-hetero-sigmatropic rearrangement to introduce sulfur atom at C-20 position, and the intramolecular nucleophilic attack of the C-20 thiol group at C-5 to form the thietane ring. The isoazole and pyrazole rings were formed from the direct condensation of the C-20 aldehyde with hydrazine or protected hydroxylamine followed by the intramolecular nucleophilic cyclization

Synthesized both 3’-cyclobutyl-Taxol (12 steps) and 3’-cyclopyropyl-Taxol (15 steps).

Combined chemical and enzymatic synthesis of optically active -lactams.

Evaluated the synthesis feasibility on synthesis of Taxol analogs by replacing the oxetane ring with cyclobutyl ring.

WEST VIRGINIA UNIVERSITY, Morgantown, WV 1990 – 1995

Graduate Research Assistant, Department of Chemistry

Developed three highly efficient methods for the stereoselective synthesis of highly conjugated enynes, enediynes, and enyne-allenes (core structures for natural enediyne antitumor antibiotics and DNA cleavage reagents):

1.Stereoselective condensation of aldehydes with -(trialkylsilyl)allenylborane and Peterson olefination reactions

2.Stereoselective bromoboration of acetylene and palladium catalyzed cross-coupling reactions,

3.The palladium catalyzed coupling reaction of enyne or ene-allene iodides with 1-alkynes

Developed a novel stereoselective synthetic method for allenene nitrile

Developed one-step synthesis of bi-, tri-, and tetra-cyclic compounds (bicyclicspiro, tricyclic spiro, and tetracyclic steroidal skeleton) from acyclic enyne-allenes

RESEARCH INSTITUTE OF PETROLEUM SCIENCE, Beijing, P.R. China 1987 – 1990

R & D Chemist, Division of Chemical Process Development

Evaluated the synthesis of Ziegler-Natta catalysts and petroleum additives.

Discovered asphalt-solidifying reagents for nuclear waste treatment.

Education

Ph.D., Organic Chemistry, Chemistry Department, West Virginia University

Research Advisor: Professor Kung K. Wang

Thesis title “Stereoselective synthesis of enynes, enyne-allenes, and enediynes; and a one-step construction of fused tricyclic and tetracyclic structures from acyclic enyne-allenes”

Master of Science, Organic Chemistry, Chemistry Department, Nankai University, Tianjin, P. R. China

Bachelor of Science, Organic Chemistry, Chemistry Department, Nankai University, Tianjin, P. R. China

Continuing Education

ACS Short Courses and on-site training:

Introduction to Drug metabolism: Role and Practice in Drug Discovery and Development

BioMed CAChe Molecular modeling in Drug Design (on site training at GPC-Biotech)

Fundamentals of Clinical trials online (edx)

Pharmacology for Chemist

The Organic Chemistry of Drug Design and Drug Action

Heterocyclic Chemistry.

Affiliations

Member of American Chemical Society (both organic and medicinal chemistry divisions)

Patent Applications and Publications

1.Discovery and Optimization of Quinolinone Derivatives as Potent, Selective and Orally Bioavailable mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors. Lin, J.; Lu, W.; Caravella, J.; Campbell, A.; Castro, J.; Clarke, A.; Diebold, B.; Diep, H.; Ericsson, A. Fritzen, E.; Gotur, D.; Gustafson, G.; Hubbs, S.; Josephine, H.; Katz, A.; Kauffman, G.; Kershaw, M.; Lancia, D.; Luke, G.; Shelekhin, T.; Toms, A.; Wang, . L.; Wang, Z. White, A.; Yao, L.; Bair, K.; Barr, K.; Dinsmore, D.; Escobedo, J.; Kley, N.; Kyranos, J.; Walker, D.; and Ashwell. S. Submitted to JMC.

2.Discovery and Optimization of Novel Piperazines as Potent Inhibitors of Fatty Acid Synthase (FASN) Martin, M.; Lancia, D.; Schiller, S.; Li, H.; Wang, Z.; Lancia, D.; Toms, A.; Bair, K.; Castro, J.; Fessler, S.; Gotur, D.; Hubbs, S.; Kauffman, G.; Kershaw, M.; Luke, G.; McKinnon, C.; Yao, L.; Lu, W.; and Millan, D. Submitted to Bioorg Med Chem Lett.

3.Preparation of pyrrolopyrrole compositions as pyruvate kinase (PKR) activators. Ericsson, A.; Green, N.; Gustafson, G.; Han, B.; Lancia, D.; Mitchell, L.; Richard, D.; Shelekhin, T.; Smith, C.; Wang, Z. PCT Int. Appl. (2018), WO 201-***-****

4.Preparation of thienopyridine carboxamides as ubiquitin- specific protease inhibitors. Guerin, D.; Bair, K..; Caravella, J..; Ioannidis, S.; Lancia, D.; Li, H.; Mischke, S.; Ng, P, Richard, D.; Schiller, S.; Shelekhin, T.; Wang. Z. PCT Int. Appl. (2017), WO 201-***-****

5.Preparation of thienopyridine carboxamides as ubiquitin- specific protease inhibitors. Guerin, D.; Bair, K..; Caravella, J.; Ioannidis, S.; Lancia, D..; Li, H.; Mischke, S.; Ng, P.; Richard, D.; Schiller, S..; Shelekhin, T.; Wang, Z. PCT Int. Appl. (2017), WO 201-***-****

6.Preparation of purinones as ubiquitin- specific protease 1 inhibitors. Buckmelter, A.; Ioannidis, S.; Follows, B.; Gustafson, G.; Wang, M.; Caravella, J.; Wang, Z.; Fritzen, E.; Lin, J. U.S. Pat. Appl. Publ. (2017), US 201-***-****

7.Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors. Ashwell, S.; Campbell, A.; Caravella, J.; Diebold, B.; Ericsson, A.; Gustafson, G.; Lancia, D.; Lin, J.; Lu, W.; Wang, Z. PCT Int. Appl. (2016), WO 201-***-****.

8.Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors. Ashwell, S.; Campbell, A.; Caravella, J.; Diebold, B.; Ericsson, A.; Gustafson, G.; Lancia, D.; Lin, J.; Lu, W.; Wang, Z. PCT Int. Appl. (2016), WO 201-***-****

9.Preparation of phenyl quinolinone derivatives as mutant- isocitrate dehydrogenase inhibitors Ashwell, S.; Campbell, A.; Caravella, J.; Diebold, B.; Ericsson, A.; Gustafson, G.; Lancia, D. Lin, J.; Lu, W.; Wang, Z. PCT Int. Appl. (2016), WO 201-***-****

10.Preparation of 3 2- oxo- 1, 2- dihydropyridin- 2- yl) amino] methyl 1, 2- dihydroquinolin- 2- one and quinoxalin- 2- one derivatives as mutant- isocitrate dehydrogenase inhibitors Ashwell, S.; Campbell, A.; Caravella, J.; Diebold, B.; Ericsson, A.; Gustafson, G.; Lancia, Da.; Lin, J.; Lu, W.; Wang, Z. PCT Int. Appl. (2016), WO 201-***-****.

11.Preparation of [(pyridinylamino) ethyl or (pyridinylamino) methyl] quinolinone derivatives as mutant- isocitrate dehydrogenase inhibitors Ashwell, S.; Campbell, A.; Caravella, J.; Diebold, B.; Ericsson, A.; Gustafson, G.; Lancia, D.; Lin, J.; Lu, W.; Wang, Z. PCT Int. Appl. (2016), WO 201-***-****

12.Identification of nicotinamide phosphoribosyl transferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility. Zak, M.; Liederer, B.; Sampath, D.; Yuen, P.; Bair, K.; Baumeister,T.; Buckmelter, A.; Clodfelter, K.; Cheng, E.; Crocker, L.; Fu, B.; Han, B.; Li, G.; Ho, Y.; Lin, J.; Liu, X., Ly, J.; O'Brien, T.; Reynolds, D.; Skelton, N.; Smith, C.; Tay, S.; Wang, W.; Wang, Z.; Xiao, Y.; Zhang, L.; Zhao, G.; Zheng, X.; Dragovich, P. Bioorg Med Chem Lett., (2014), 25, 529-541.

13.Discovery of potent and efficacious cyanoguanidine- containing nicotinamide phosphoribosyl transferase (Nampt) inhibitors. Zheng, X.; Baumeister, T.; Buckmelter, A..; Caligiuri, M.; Clodfelter, K.; Han, B.; Ho, Y.; Kley, N.; Lin, J.; Reynolds, D.; Sharma, G.; Smith, Chase C.; Wang, Z.; Dragovich, P.; Oh, A.; Wang, W.; Zak, M.; Wang, Y.; Yuen, P.; Bair, K. Bioorg. & Med. Chem. Lett., (2014), 24(1), 337-343

14.Identification of amides derived from 1H- pyrazolo [3, 4- b] pyridine- 5- carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyl transferase (NAMPT). Zheng, X.; Bair, K..; Bauer, P.; Baumeister, T.; Bowman, K..; Buckmelter, A.; Caligiuri, M.; Clodfelter, K.; Feng, Y.; Han, B.; Ho, Y.; Kley, N.; Li, H.; Liang, X.; Liederer, B.; Lin, J.; Ly, J.; O'Brien, T.; Oeh, J.; Oh, A.; Reynolds, D.; Sampath, D.; Sharma, G.; Skelton, N.; Smith, C.; Tremayne, J.; Wang, L.; Wang, W.; Wang, Z.; Wu, H.; Wu, J.; Xiao, Y; Yang, G.; Yuen, P.; Zak, M.; Dragovich, P. Bioorg. & Med. Chem. Lett., (2013), 23(20), 5488-5497

15.Alkyl- and di- substituted amido- benzyl sulfonamide derivatives. Bair, K.; Baumeister, T.; Buckmelter, A.; Clodfelter, K.; Gunzner-Toste, J.; Han, B.; Lin, J.; Reynolds, D..; Smith, C.; Wang, Z.; Zak, M.; Zheng, X.; Zhao, G. PCT Int. Appl. (2013), WO2013130943.

16.Preparation of amid benzyl sulfone and sulfoxide derivatives as NAMPT inhibitors. Bair, K..; Baumeister, T.; Buckmelter, A.; Clodfelter, K.; Dragovich, P.; Gosselin, F.; Gunzner-Toste, J.; Han, B.; Lin, J.; Liu, X.; Reynolds, D.; Smith, C.; Wang, Z.; Zak, M.; Zhang, Y.; Zhao, G.; Zheng, X.; Yuen, P. PCT Int. Appl. (2013), WO2013127266

17.Preparation of amid benzyl sulfone and sulfoxide derivatives as NAMPT inhibitors. Bair, K.; Baumeister, T.; Buckmelter, A.; Clodfelter, K.; Dragovich, P.; Han, B. Lin, J.; Liu, X.; Reynolds, D.; Smith, C.; Wang, Z.; Yuen, P.; Zak, M.; Zhang, Y.; Zheng, X.; Zhao, G. PCT Int. Appl. (2013), WO2013127268

18.Structure- Based Discovery of Novel Amide- Containing Nicotinamide Phosphoribosyl transferase (Nampt) Inhibitors. Zheng, X.; Bauer, Paul; Baumeister, T.; Buckmelter, A.; Caligiuri, M.; Clodfelter, K.; Han, B.; Ho, Y.; Kley, N.; Lin, J.; Reynolds, D.; Sharma, G.; Smith, C.; Wang, Z.; Dragovich, P.; Gunzner-Toste, J.; Liederer, B.; Ly, J.; O'Brien, T.; Oh, A.; Wang, L.; Wang, W.; Xiao, Y.; Zak, M.; Zhao, G.; Yuen, P.; Bair, K. J. Med. Chem., (2013), 56(16), 6413-6433

19.Discovery of potent and efficacious urea- containing nicotinamide phosphoribosyl transferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties. Gunzner-Toste, J.; Zhao, G.; Bauer, P.; Baumeister, T.; Buckmelter, A.; Caligiuri, M.; Clodfelter, K.; Fu, B.; Han, B.; Ho, Y.; Kley, N.; Liang, X.; Liederer, B..; Lin, J.; Mukadam, S.; O'Brien, T.; Oh, A.; Reynolds, D.; Sharma, G.; Skelton, N.; Smith, C.; Sodhi, J.; Wang, W.; Wang, Z.; Xiao, Y.; Yuen, P.; Zak, M.; Zhang, L.; Zheng, X.; Bair, K.; Dragovich, P. Bioorg. & Med. Chem. Lett., (2013), 23(12), 3531-3538

20.Structure- Based Identification of Ureas as Novel Nicotinamide Phosphoribosyl transferase (Nampt) Inhibitors. Zheng, X.; Bauer, P.; Baumeister, T.; Buckmelter, A.; Caligiuri, M.; Clodfelter, K..; Han, B.; Ho, Y.; Kley, N.; Lin, J.; Reynolds, D.; Sharma, G.; Smith, C.; Wang, Z.; Dragovich, P.; Oh, A.; Wang, W.; Zak, M.; Gunzner-Toste, J.; Zhao, G.; Yuen, P.; Bair, K. J. Med. Chem. (2013), 56(12), 4921-4937

21.Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyl transferase (NAMPT) and their preparation. Bair, K.; Baumeister, T.; Buckmelter, A.; Clodfelter, K.; Han, B; Kuntz, J.; Lin, J.; Reynolds, D.; Smith, C.; Wang, Z.; Zheng, X. PCT Int. Appl. (2012), WO2012154194

22.Preparation of pyridinylprop- 2- enamide compounds as NAMPT inhibitors. Bair, K.; Baumeister, T.; Buckmelter, A.; Clodfelter, K.; Han, B.; Lin, J.; Reynolds, D.; Smith, C.; Wang, Z.; Zheng, X. PCT Int. Appl. (2012), WO2012150952

23.Preparation of 4 pyridin- 3- ylmethyl) aminocarbonyl] amino] benzenesulfone derivatives as NAMPT inhibitors for therapy of diseases such as cancer. Bair, K.; Baumeister, T.; Buckmelter, A.; Clodfelter, K.; Han, B.; Lin, J.; Reynolds, D.; Smith, C.; Wang, Z.; Zheng, X.; Yuen, P. PCT Int. Appl. (2012), WO2012031196

24.Guanidine compounds and compositions for the inhibition of NAMPT and their preparation. Bair, K.; Buckmelter, A.; Han, B.; Lin, J.; Reynolds, D.; Smith, C.; Wang, Z.; Zheng, X. PCT Int. Appl. (2012), WO2012031199

25.N- (sulfonyl benzyl) heteroaryl carboxamide derivatives as nicotinamide phosphoribosyl transferase (NAMPT) inhibitors and their preparation and use for the treatment of diseases. Bair, K.; Baumeister, T.; Buckmelter, A.; Clodfelter, K.; Dragovich, P.; Gosselin, F.; Han, B.; Lin, J.; Reynolds, D.; Roth, B.; Smith, C.; Wang, Z.; Yuen, P.; Zheng, X. PCT Int. Appl. (2012), WO2012031197

26.Process for the preparation of nucleoside tetraphosphate analogs. Baldino, C.; Cook, P.; Ghosh, S.; Varady, l., Waldbach, T.; Wang, Z. PCT Int. Appl. (2009) WO2009102928

27.Inhibitors of cyclin-dependent kinases, compositions and uses related thereto. Bockovich, N.; Kluge, A.; Oalmann, C.; Murthi, K.; Ram, S.; Wang, Z.; Huang. J. PCT Int Appl. (2005) WO200506375

28.Pyrazole derivative inhibitors of cyclin-dependent kinases for use as antitumor and antiviral agents. Becker, F.; Bockovich, N.; Come, J.; Kluge. A.; Murthi, K.; Oalmann, C.; Ram, S.; Wang, Z. U.S. Pat. Appl. Publ. (2004) US2004266854

29.Preparation of pyrazole derivatives as inhibitors of cyclin-dependent kinases, compositions and uses related thereto. Bockovich, N.; Kluge, A.; Oalmann, C.; Murthi, K; Ram, S.; Wang, Z.; Huang, J. PCT Int. Appl. (2004) WO2004092139

30.Preparation arylalkyl substituted pyrazolo [5, 4-d] pyrimidines and related analogs as inhibitors of Cyclin Dependent Kinases. Bockovich, N.; Kluge, A.; Ram, S.; Wang, Z.; Oalmann, C.; Murthi, K. PCT Int. Appl. (2003) WO2003033499

31.Preparation of nitrogen heterocyclic compounds as inhibitors of prenyl transferases Come, J.; Murthi, K.; Wang, Z. PCT Int. Appl. (2003) WO 200-***-****

32.Preparation of diazabicyclooctanones and analogs as t-RNA synthetase inhibitors. Finn, J.; Yu, X.; Wang, Z.; Hill, J.; Keith, D.; Gallant, P.; Wendler, P. PCT Int. Appl. (2000) WO 200*******

33.Preparation of tetracyclic heterocycles as bactericides and medical fungicides. Finn, J.; Yu, X.; Wang, Z.; Hill, J.; Keith, D.; Gallant, P.; Wendler, P. PCT Int. Appl. (2000) WO2000017206

34.A series of spirocyclic analogues as potent inhibitors of bacterial phenylalanyl-t-RNA synthetases. Yu, X.; Finn, J.; Hill, J.; Wang, Z.; Keith, D.; Silverman, J.; and Oliver, N. Bioorg. & Med. Chem. Lett., (2004) 14, 1339-1342

35.A series of heterocyclic inhibitors of phenylalanyl-t-RNA synthetases with antibacterial activity. Yu, X.: Finn, J.; Hill, J.; Wang, Z.; Keith, D.; Silverman, J.; and Oliver, N. Bioorg. & Med. Chem. Lett., (2004) 14, 1343-1346

36. Cascade radical cyclization of biradicals generated from (Z)-1,2,4-heptatrien-6-ynes. Wang, K.; Wang, Z.; Tarli, A.; Gannett, P. J. Am. Chem. Soc. (1996), 118, 107**-*****

37.Synthesis and cycloaromatization of (Z)-1,2,4-heptatrien-6-ynes and (Z)- 2,4,5-hexatrienitriles. Wang, K.; Wang, Z.; Sattsangi, P. D. J. Org. Chem. (1996), 61, 1516-1518

38. Stereoselective synthesis of enediynes and enyne-allenes having a tetra substituted central carbon-carbon double bond. Wang, K.; Wang, Z. J. Org. Chem. (1994), 59, 4738-4742

39.A convenient procedure for the synthesis of enyne-allenes. Wang, K.; Wang, Z. Tetrahedron lett., (1994), 35, 1829-1832

40.Stereoselective synthesis of enediynes and enynes by condensation of aldehydes with -(trialkylsilyl)allenylborane. Wang, K.; Wang, Z.; Gu, Y. G. Tetrahedron lett., (1993), 34, 8391-8394

41.Stereoselective synthesis of enediynes and enyne-allene via r-(trialkylsilyl)allenylborane. Wang, K.; Andemichael, Y. W.; Gu, Y.G.; Wang, Z. Proceeding of Current Topics in the Chemistry of Boron Edited by G. W. Kabalka, (1994), 40-43

42.Extraction of gold using -alkyl substituted pyridines. (1). Determination of the ionization constant of -alkyl substituted pyridines and the extraction behavior of gold. Gan, W.; Zhang, Y.; Dong, L.; Wang, Z.; Nie, Z.; Liang, S. Gaodeng Huaxue Xuebao (199*-**-***-***

43.Indenopyrazoles: Potent, broad-spectrum cyclin dependent kinase inhibitors. Oalmann, C.; Bockovich, N.; Caligiuri, M.; Kaplan, F.; Huang, J.; Kluge, A.; Lamphere, L.; Mohamud, M.; Richard, J.; Ram, S.; Tsaioun, K.; Wang, S.; Wang, Z. The 232nd ACS National Meeting, San Francisco, CA. Sept (2006) Medi-100

44.Stereoselective synthesis of enediynes and enyne-allenes having a tetrasubstituted central carbon-carbon double bond. Wang, Z.; Wang, K. The 208th ACS National Meeting, Washington D. C., Aug (1994)

45.Stereoselective synthesis of enediynes. Wang, K.; Wang, Z. The 206th ACS National Meeting, Chicago, Illinois, Aug (1993)

46.Hydrozirconation of amides by Schwartz’s reagent. Wang, T.; Wang, Z. The 4th Chineses National Organometallic Meeting, Lanzhou, P. R. China, (1988)

Contact this candidate